LISBON, Portugal — A novel oral drug offers clinically meaningful improvements in exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) and reduces the burden of limiting symptoms, new data from the SEQUOIA-HCM trial reveal. Aficamten is an investigational next-generation selective cardiac myosin inhibitor that reduces left ventricular contractility…
